Rare Disease Research Pipeline

According to NIH funding data, public investment in this condition is currently at a very large level, and the direction of that funding is rising year on year. This is an encouraging signal for patients, as sustained and growing public funding tends to support ongoing research into causes, mechanisms and potential treatments. While funding alone does not guarantee new therapies, it does suggest that scientific interest in this condition is strong and building momentum.

Registry data shows that clinical trials are active at both early and late stages of development. Early stage trials, such as Phase 1 and Phase 2, suggest researchers are still exploring how potential treatments work and whether they are safe. The presence of later stage activity, such as Phase 3, is particularly meaningful for patients, as it indicates that some approaches have already cleared early hurdles and are being tested more rigorously in larger groups of people.

For Australian patients, the current picture requires some caution and context. No TGA approval has been recorded for treatments in this area, which means no therapy has yet been formally cleared for use in Australia through that pathway. No PBS listing has been recorded either, so subsidised access through the standard Australian government medicines scheme is not currently in place. Patients are encouraged to speak with their treating specialist about whether any clinical trials or other access pathways may be relevant to their individual situation.

This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.